Where are you?
To give you the most accurate information about our products and what we can do for you, we need to direct you to the right site.
Resources
Filter by type
Kuros Interim Results, 2022
English version
Press Release, 9 August 2022
Adhoc Press Release
Kuros Biosciences reports results for the first six months of 2022
24th Ordinary General Meeting, 2022
German version
Press Release, 8 June 2022
Adhoc Press Release
Annual General Meeting of Kuros Biosciences approves all resolutions
Press Release, 2 June 2022
Adhoc Press Release
Kuros Biosciences: Completion of the acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals triggers a $5 million milestone payment
Press Release, 31 May 2022
Kuros Biosciences announces favorable preliminary results of MagnetOs as standalone alternative to autograft in first randomized controlled trial